Resapp Health

Resapp Health Equity

The The Equity of Resapp Health (RAP.AX) as of Oct 9, 2026 is 1.95 M AUD. In the previous year, The Equity was 3.27 M AUD — a change of -40.44% (lower).

Equity

1.95 MAUD

YoY

-40.44%

Last updated:

In 2024, Resapp Health's equity was 1.95 M AUD, a -40.44% increase from the 3.27 M AUD equity in the previous year.

The Resapp Health Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
11.35 M AUD
Jan 1, 2018
5.54 M AUD
Jan 1, 2019
7.69 M AUD
Jan 1, 2020
7.00 M AUD
Jan 1, 2021
7.60 M AUD
Jan 1, 2022
689,561.00 AUD
Jan 1, 2023
3.27 M AUD
Jan 1, 2024
1.95 M AUD
The Resapp Health Equity history
YEAREquityYoY
1.95 MAUD-40.44%
3.27 MAUD+374.59%
689,561.00AUD-90.93%
7.60 MAUD+8.65%
7.00 MAUD-8.96%
7.69 MAUD+38.70%
5.54 MAUD-51.16%
11.35 MAUD-29.27%
16.05 MAUD+3,208.93%
484,941.00AUD+299.42%
121,412.00AUD—
Access this data via the Eulerpool API
Get Free API Key

Resapp Health Stock analysis

What does Resapp Health do? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Resapp Health's Equity

Resapp Health's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Resapp Health's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Resapp Health's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Resapp Health's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Resapp Health’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Resapp Health stock

The Equity of Resapp Health is 1.95 M AUD in 2024.

The Equity of Resapp Health changed from 3.27 M AUD to 1.95 M AUD, representing a -40.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Resapp Health since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Resapp Health historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Resapp Health

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Resapp Health